A PET study with [11-C]raclopride in Parkinson's disease: Preliminary results on the effect of amantadine on the dopaminergic system

M. A. Volonté, R. M. Moresco, C. Gobbo, C. Messa, A. Carpinelli, G. Rizzo, G. Comi, F. Fazio

Research output: Contribution to journalArticlepeer-review

Abstract

Amantadine has been proved to be beneficial in Parkinson's disease. Although it is still uncertain which neurochemical events are modified at therapeutic doses, an increase in dopaminergic tone secondary to NMDA receptor blockade and a direct inhibition of the glutamatergic over-activity have been suggested to be involved in its clinical effects. The aim of this study was to evaluate the effects of amantadine on the dopaminergic system by measuring the in vivo binding of [11-C]raclopride to D2 dopamine receptors in the basal ganglia of 6 patients with idiopathic Parkinson's disease. Each patient underwent a PET study, before and after 14 days of treatment with amantadine (200 mg/day). Repeated treatment with therapeutic doses of amantadine induced a moderate increase in the in vivo binding of [11-C]raclopride in the putamen of PD patients. This observation indicates that in PD patients, 200 mg/day amantadine does not produce an increase in extracellular levels of dopamine sufficiently to inhibit raclopride binding or that, if present, is it masked by a concurrent increase in receptor availability, as recently reported in rat striatum.

Original languageEnglish
Pages (from-to)107-108
Number of pages2
JournalNeurological Sciences
Volume22
Issue number1
DOIs
Publication statusPublished - Feb 2001

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'A PET study with [11-C]raclopride in Parkinson's disease: Preliminary results on the effect of amantadine on the dopaminergic system'. Together they form a unique fingerprint.

Cite this